JP2010518860A - Ｌｙｎキナーゼの活性化剤の同定方法 - Google Patents

Ｌｙｎキナーゼの活性化剤の同定方法 Download PDF

Info

Publication number
JP2010518860A
JP2010518860A JP2009550979A JP2009550979A JP2010518860A JP 2010518860 A JP2010518860 A JP 2010518860A JP 2009550979 A JP2009550979 A JP 2009550979A JP 2009550979 A JP2009550979 A JP 2009550979A JP 2010518860 A JP2010518860 A JP 2010518860A
Authority
JP
Japan
Prior art keywords
test compound
lyn kinase
minutes
substrate
atp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009550979A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010518860A5 (enExample
Inventor
アンドルー・レオウム
マイクル・サポリト
Original Assignee
メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド filed Critical メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド
Publication of JP2010518860A publication Critical patent/JP2010518860A/ja
Publication of JP2010518860A5 publication Critical patent/JP2010518860A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2009550979A 2007-02-20 2008-02-20 Ｌｙｎキナーゼの活性化剤の同定方法 Pending JP2010518860A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89063207P 2007-02-20 2007-02-20
PCT/US2008/054361 WO2008103692A2 (en) 2007-02-20 2008-02-20 Methods of identifying activators of lyn kinase

Publications (2)

Publication Number Publication Date
JP2010518860A true JP2010518860A (ja) 2010-06-03
JP2010518860A5 JP2010518860A5 (enExample) 2011-04-07

Family

ID=39710712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009550979A Pending JP2010518860A (ja) 2007-02-20 2008-02-20 Ｌｙｎキナーゼの活性化剤の同定方法

Country Status (13)

Country Link
US (1) US20100152215A1 (enExample)
EP (1) EP2120581A4 (enExample)
JP (1) JP2010518860A (enExample)
KR (1) KR20100014480A (enExample)
CN (1) CN101686686A (enExample)
AU (1) AU2008218765A1 (enExample)
BR (1) BRPI0807928A2 (enExample)
CA (1) CA2678813A1 (enExample)
IL (1) IL200429A0 (enExample)
MX (1) MX2009008874A (enExample)
NZ (1) NZ579227A (enExample)
WO (1) WO2008103692A2 (enExample)
ZA (1) ZA200905776B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
GB201010196D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Methods
CN102507707B (zh) * 2011-10-12 2015-10-21 山东大学 一种检测龈沟液中蛋白裂解酶含量的方法
CN104271140B (zh) * 2011-12-12 2016-11-23 梅里奥尔医药I公司 I型和ii型糖尿病的治疗
US9827222B2 (en) * 2013-07-01 2017-11-28 Emory University Treating or preventing nephrogenic diabetes insipidus
WO2015099094A1 (ja) 2013-12-27 2015-07-02 国立大学法人東京医科歯科大学 アルツハイマー病及び前頭側頭葉変性症の診断方法、診断薬、治療薬、及びこれら薬剤のスクリーニング方法
AU2019223911A1 (en) * 2018-02-21 2020-07-23 Melior Pharmaceuticals I, Inc. Treatment of liver diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002068394A1 (en) * 2001-02-22 2002-09-06 Glaxo Group Limited Quinoline derivative as tyrosine kinase inhibitor
WO2002095058A2 (en) * 2001-05-24 2002-11-28 Regents Of The University Of California Emission ratiometric indicators of phosphorylation
JP2007037546A (ja) * 2005-07-29 2007-02-15 F Hoffmann La Roche Ag 一般的キナーゼアッセイ法
JP5113752B2 (ja) * 2005-08-22 2013-01-09 メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド Ｌｙｎキナーゼの活性を調節し、関連する疾患を治療するための方法および製剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US3922345A (en) * 1971-10-29 1975-11-25 Pfizer Pyrimidinones and hydroxy pyrimidines
US4080454A (en) * 1976-07-16 1978-03-21 Pfizer Inc. 5-M-Tolyloxyuracil, anti-ulcer agent
US4612376A (en) * 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
SE9203753D0 (sv) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
US5476855A (en) * 1993-11-02 1995-12-19 Mahmoud H. el Kouni Enzyme inhibitors, their synthesis and methods for use
US20020019346A1 (en) * 1997-05-21 2002-02-14 Children's Medical Center Corporation Treatment of prostate cancer by inhibiting lyn tyrosine kinase
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6410255B1 (en) * 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
EP1618094B1 (en) * 2003-04-30 2007-09-05 The Institutes for Pharmaceutical Discovery, LLC Substituted heteroaryls as inhibitors of protein tyrosine phosphatases
EP1541694A1 (en) * 2003-12-12 2005-06-15 Sirenade Pharmaceuticals AG Methods of identifying, selecting and/or characterizing compounds which modulate the activity of a Src family kinase
US20060035302A1 (en) * 2004-06-21 2006-02-16 Applera Corporation Kinase substrates with multiple phosphorylation sites
JP2008521900A (ja) * 2004-11-30 2008-06-26 アムジエン・インコーポレーテツド キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用
ITUD20050112A1 (it) * 2005-07-01 2007-01-02 Gaetano Azzolina Dispositivo di assistenza cardiocircolatoria
TWI273177B (en) * 2005-07-08 2007-02-11 Ama Precision Inc Fan apparatus with adapting device
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002068394A1 (en) * 2001-02-22 2002-09-06 Glaxo Group Limited Quinoline derivative as tyrosine kinase inhibitor
WO2002095058A2 (en) * 2001-05-24 2002-11-28 Regents Of The University Of California Emission ratiometric indicators of phosphorylation
JP2007037546A (ja) * 2005-07-29 2007-02-15 F Hoffmann La Roche Ag 一般的キナーゼアッセイ法
JP5113752B2 (ja) * 2005-08-22 2013-01-09 メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド Ｌｙｎキナーゼの活性を調節し、関連する疾患を治療するための方法および製剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6012060023; Ｊ．　Ｉｍｍｕｎｏｌ． Ｖｏｌ．１５５, 1995, ｐ．４５９６-４６０３ *
JPN6012060024; 'Ｓｒｃ　Ｋｉｎａｓｅ' ［ｏｎｌｉｎｅ］ , 20060112 *
JPN6012060026; Ｊ．　Ｍｅｄ．　Ｃｈｅｍ． Ｖｏｌ．２３, 1980, ｐ．１０２６-１０３１ *

Also Published As

Publication number Publication date
NZ579227A (en) 2012-11-30
EP2120581A4 (en) 2011-03-16
MX2009008874A (es) 2009-10-20
CN101686686A (zh) 2010-03-31
ZA200905776B (en) 2010-05-26
EP2120581A2 (en) 2009-11-25
WO2008103692A2 (en) 2008-08-28
AU2008218765A1 (en) 2008-08-28
US20100152215A1 (en) 2010-06-17
BRPI0807928A2 (pt) 2014-07-08
IL200429A0 (en) 2010-04-29
CA2678813A1 (en) 2008-08-28
WO2008103692A3 (en) 2008-10-23
KR20100014480A (ko) 2010-02-10

Similar Documents

Publication Publication Date Title
TWI642434B (zh) 用於預防和／或治療中樞神經系統之變性疾病的新穎組合物
JP2010518860A (ja) Ｌｙｎキナーゼの活性化剤の同定方法
US12064432B2 (en) Treatment of adipocytes
JP2015193638A (ja) 糖尿病の処置方法
JP7046250B2 (ja) がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
CN101668530A (zh) 激活irs-1和akt的方法
KR101452518B1 (ko) Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한방법 및 제제
US20210106581A1 (en) Treatment Of Liver Diseases
Reaume et al. Treatment of adipocytes
BR112019021140B1 (pt) Composição, e, uso de um ativador de lyn cinase e de um agonista de trpm8

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130423